ArticleThe Journal of urology2014

Re: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.

Samir S TanejaPubMed ↗Publisher ↗

No numbers read from the abstract.